Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses

Vaccine

Volumn 27, Issue 47, 2009, Pages 6512-6521

  Price, Graeme E ^a   Soboleski, Mark R ^a   Lo, Chia Yun ^a   Misplon, Julia A ^a   Pappas, Claudia ^b   Houser, Katherine V ^b   Tumpey, Terrence M ^b   Epstein, Suzanne L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Cold adapted; DNA vaccine; Ferret; H5N1; Heterosubtypic immunity; Immunization; Influenza; Intramuscular; Intranasal; Mice; Pandemic; Prime boost; Recombinant adenovirus; Systemic; Vaccine

Indexed keywords

ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN A; PRIMER DNA; PROTEIN M2; VIRUS NUCLEOPROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLD ACCLIMATIZATION; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; FERRET; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; LUNG; MALE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; FERRETS; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; T-LYMPHOCYTES; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 70350567189     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.053     Document Type: Article

References (48)

1. Carrat F., and Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25 39-40 (2007) 6852-6862
2. Subbarao K., and Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7 4 (2007) 267-278
3. Schulman J.L., and Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 89 (1965) 170-174
4. Liang S., Mozdzanowska K., Palladino G., and Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152 4 (1994) 1653-1661
5. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 46-47 (2005) 5404-5410
6. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3 5 (2007) 157-164
7. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 5102 (1993) 1745-1749
8. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26 17 (2008) 2062-2072
9. Epstein S.L. Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti Infect Ther 1 4 (2003) 627-638
10. Fazekas de St Groth S., and Donnelley M. Studies in experimental immunology of influenza. IV. The protective value of active immunization. Aust J Exp Biol Med Sci 28 1 (1950) 61-75
11. Murphy B.R., and Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15 2 (2002) 295-323
12. Smeenk C.A., and Brown E.G. The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol 68 1 (1994) 530-534
13. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79 18 (2005) 11788-11800
14. Epstein S.L., Tumpey T.M., Misplon J.A., Lo C.Y., Cooper L.A., Subbarao K., et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8 8 (2002) 796-801
15. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 10 (1999) 1157-1163
16. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13 3 (2007) 426-435
17. Gao X.M., Liew F.Y., and Tite J.P. Identification and characterization of T helper epitopes in the nucleoprotein of influenza A virus. J Immunol 143 9 (1989) 3007-3014
18. Eliasson D.G., El Bakkouri K., Schon K., Ramne A., Festjens E., Lowenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26 9 (2008) 1243-1252
19. Deng Y., Yewdell J.W., Eisenlohr L.C., and Bennink J.R. MHC affinity, peptide liberation, T-cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 158 4 (1997) 1507-1515
20. Sweet C., Fenton R.J., and Price G.E. The ferret as an animal model of influenza virus infection. In: Zak O., and Sande M. (Eds). Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy (1999), Academic Press, London 989-998
21. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197 12 (2008) 1643-1652
22. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3 6 (2008) e2517
23. Rimmelzwaan G.F., Boon A.C., Voeten J.T., Berkhoff E.G., Fouchier R.A., and Osterhaus A.D. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 103 1-2 (2004) 97-100
24. Zharikova D., Mozdzanowska K., Feng J., Zhang M., and Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79 11 (2005) 6644-6654
25. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 25-26 (2002) 3104-3112
26. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., and Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64 3 (1990) 1375-1377
27. Zebedee S.L., and Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62 8 (1988) 2762-2772
28. Black R.A., Rota P.A., Gorodkova N., Klenk H.D., and Kendal A.P. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 74 Pt 1 (1993) 143-146
29. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3 (2006) 102
30. Doherty P.C., and Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 118 10 (2008) 3273-3275
31. Hikono H., Kohlmeier J.E., Ely K.H., Scott I., Roberts A.D., Blackman M.A., et al. T-cell memory and recall responses to respiratory virus infections. Immunol Rev 211 (2006) 119-132
32. + T-cells in the lung airways. J Immunol 178 8 (2007) 4721-4725
33. + T-cells. Proc Natl Acad Sci U S A 98 11 (2001) 6313-6318
34. + memory T-cell subsets. Proc Natl Acad Sci U S A 101 15 (2004) 5610-5615
35. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., and Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T-cells that give rise to long-lived memory cells. Nat Immunol 4 12 (2003) 1191-1198
36. Hogan R.J., Usherwood E.J., Zhong W., Roberts A.D., Dutton R.W., Harmsen A.G., et al. Activated antigen-specific CD8(+) T-cells persist in the lungs following recovery from respiratory virus infections. J Immunol 166 3 (2001) 1813-1822
37. + T-cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72 7 (1998) 5648-5653
38. Belz G.T., Wodarz D., Diaz G., Nowak M.A., and Doherty P.C. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 76 23 (2002) 12388-12393
39. Riberdy J.M., Christensen J.P., Branum K., and Doherty P.C. Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J Virol 74 20 (2000) 9762-9765
40. + CTL against influenza-sensitized autologous splenocytes. Immunol Lett 46 1-2 (1995) 67-73
41. + T-cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. J Virol 70 2 (1996) 1288-1291
42. Guillot L., Le Goffic R., Bloch S., Escriou N., Akira S., Chignard M., et al. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280 7 (2005) 5571-5580
43. Wang J.P., Bowen G.N., Padden C., Cerny A., Finberg R.W., Newburger P.E., et al. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 112 5 (2008) 2028-2034
44. Appledorn D.M., Patial S., McBride A., Godbehere S., Van Rooijen N., Parameswaran N., et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 181 3 (2008) 2134-2144
45. Hartman Z.C., Appledorn D.M., and Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132 1-2 (2008) 1-14
46. Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008; 26(34):4299-4303.
47. Kutzler M.A., and Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 9 10 (2008) 776-788
48. Lee L.Y., Ha D.L., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T-cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 10 (2008) 3478-3490